Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-cash Items (2016 - 2025)

Syndax Pharmaceuticals has reported Non-cash Items over the past 11 years, most recently at $7.5 million for Q4 2025.

  • Quarterly results put Non-cash Items at $7.5 million for Q4 2025, down 22.78% from a year ago — trailing twelve months through Dec 2025 was $7.5 million (down 22.78% YoY), and the annual figure for FY2025 was $7.5 million, up 13.13%.
  • Non-cash Items for Q4 2025 was $7.5 million at Syndax Pharmaceuticals, down from $9.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for SNDX hit a ceiling of $88.0 million in Q4 2022 and a floor of $83000.0 in Q1 2022.
  • Median Non-cash Items over the past 5 years was $3.9 million (2022), compared with a mean of $21.8 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 103.21% in 2021 and later tumbled 99.74% in 2022.
  • Syndax Pharmaceuticals' Non-cash Items stood at $68.6 million in 2021, then increased by 28.29% to $88.0 million in 2022, then tumbled by 37.41% to $55.1 million in 2023, then tumbled by 82.31% to $9.7 million in 2024, then fell by 22.78% to $7.5 million in 2025.
  • The last three reported values for Non-cash Items were $7.5 million (Q4 2025), $9.7 million (Q4 2024), and $55.1 million (Q4 2023) per Business Quant data.